Actinium Pharmaceuticals Inc. (ATNM)’s Financial Results Comparing With Vascular Biogenics Ltd. (NASDAQ:VBLT)

Actinium Pharmaceuticals Inc. (NYSEAMERICAN:ATNM) and Vascular Biogenics Ltd. (NASDAQ:VBLT) have been rivals in the Biotechnology for quite some time. Below is a review of each business including various aspects such as institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Actinium Pharmaceuticals Inc. N/A 0.00 N/A -0.20 0.00
Vascular Biogenics Ltd. 1 77.57 N/A -0.52 0.00

Table 1 shows the gross revenue, earnings per share (EPS) and valuation for Actinium Pharmaceuticals Inc. and Vascular Biogenics Ltd.


Table 2 provides the return on equity, return on assets and net margins of the two firms.

Net Margins Return on Equity Return on Assets
Actinium Pharmaceuticals Inc. 0.00% -213.7% -140.7%
Vascular Biogenics Ltd. 0.00% -31.7% -27.4%

Risk & Volatility

Actinium Pharmaceuticals Inc. is 79.00% more volatile than S&P 500 due to its 1.79 beta. Competitively, Vascular Biogenics Ltd. is 134.00% less volatile than S&P 500, because of the -0.34 beta.


The Current Ratio and a Quick Ratio of Actinium Pharmaceuticals Inc. are 1.8 and 1.8. Competitively, Vascular Biogenics Ltd. has 8.3 and 8.3 for Current and Quick Ratio. Vascular Biogenics Ltd.’s better ability to pay short and long-term obligations than Actinium Pharmaceuticals Inc.

Analyst Recommendations

Recommendations and Ratings for Actinium Pharmaceuticals Inc. and Vascular Biogenics Ltd. can be find in next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Actinium Pharmaceuticals Inc. 0 0 0 0.00
Vascular Biogenics Ltd. 0 0 1 3.00

Competitively the average target price of Vascular Biogenics Ltd. is $2, which is potential 54.44% upside.

Insider and Institutional Ownership

The shares of both Actinium Pharmaceuticals Inc. and Vascular Biogenics Ltd. are owned by institutional investors at 17.6% and 25.1% respectively. Actinium Pharmaceuticals Inc.’s share held by insiders are 0.1%. Comparatively, 26.6% are Vascular Biogenics Ltd.’s share held by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Actinium Pharmaceuticals Inc. -7.69% -4.98% -21.93% -58.43% -63.91% -39.84%
Vascular Biogenics Ltd. -0.75% 1.54% 5.6% 2.33% -32.31% 36.08%

For the past year Actinium Pharmaceuticals Inc. has -39.84% weaker performance while Vascular Biogenics Ltd. has 36.08% stronger performance.


Vascular Biogenics Ltd. beats on 7 of the 8 factors Actinium Pharmaceuticals Inc.

Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops targeted payload immunotherapeutics for the treatment of advanced cancers. The companyÂ’s proprietary platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its lead product candidate is Iomab-B that is in Phase III clinical studies in refractory or relapsed acute myeloid leukemia (AML) patients over the age of 55 for hematopoietic stem cell transplant, commonly referred to as bone marrow transplant. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60; and Actimab-M that is in Phase I clinical trials for patients with relapsed or refractory multiple myeloma. In addition, it utilizes its alpha-particle immunotherapy technology platform to generate new drug candidates based on antibodies linked to the element Actinium-225 that are directed at various cancers that are blood-borne or form solid tumors. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.

Vascular Biogenics Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for cancer. The companyÂ’s program is based on its proprietary vascular targeting system platform technology, which utilizes genetically targeted therapy to destroy newly formed or angiogenic blood vessels. Its lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer; and has completed Phase II clinical trials for recurrent platinum-resistant ovarian cancer, as well as for iodine-resistant differentiated thyroid cancer. The companyÂ’s pipeline candidates also comprise VB-511, an anti-angiogenic candidate for oncology; and VB-211 and VB-411, which are pro-angiogenic candidates for the treatment of peripheral vascular diseases. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was founded in 2000 and is headquartered in Or Yehuda, Israel.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.